>6 months at -80°C.

1. Rikimaru,T. et al., Oncology 72 (1-2), 69-74 (2007).
2. Ishihama, K. et al., J Clin Pathol 60(11), 1205-10 (2007).

Application Reference(s): 
1. Structure-Activity Relationship of Propargylamine-Based HDAC Inhibitors (2017)
2. HDAC Inhibitor-Induced Mitotic Arrest Is Mediated by Eg5/KIF11 Acetylation (2017) 
3. Screening of histone deacetylase 1 inhibitors in natural products by capillary electrophoresis (2017) 
4. (±)-Applanatumines B–D: novel dimeric meroterpenoids from Ganoderma applanatum as inhibitors of JAK3 (2017)
5. Synthese, Konformationsanalyse und biologische Evaluierung von neuartigen antitumoraktiven Peptoid-Derivaten (2017)
6. Alkoxyurea-Based Histone Deacetylase Inhibitors Increase Cisplatin Potency in Chemoresistant Cancer Cell Lines (2017)
7. Discovery of an Inhibitor of the Proteasome Subunit Rpn11 (2017)
8. Dipicolinic Acid Derivatives as Inhibitors of New Delhi Metallo-β-lactamase-1  (2017)
9. Divergent JNK Phosphorylation of HDAC3 in Triple-Negative Breast Cancer Cells Determines HDAC Inhibitor Binding and ivity (2017)
10. Synthesis and Biochemical Evaluation of Biotinylated Conjugates of Largazole Analogues: ive Class I Histone Deacetylase Inhibitors (2017)
11. An azumamide C analogue without the zinc-binding functionality (2017)
12. Impact of binding mechanism on ive inhibition of histone deacetylase isoforms (2017)
13. Structure-based design and biological characterization of ive histone deacetylase 8 (HDAC8) inhibitors with anti-neuroblastoma activity (2017)
14. Design, synthesis and biological evaluation of novel hydroxamic acid based histone deacetylase 6 ive inhibitors bearing phenylpyrazol scaffold as surface recognition motif (2017)
15. Identification of histone deacetylase inhibitors with benzoylhydrazide scaffold that ively inhibit class I histone deacetylases (2015) 
16. A chimeric SERM-histone deacetylase inhibitor approach to breast cancer therapy (2014) 
17. CBP and p300 acetylate PCNA to link its degradation with nucleotide excision repair synthesis (2014)
18. Design, synthesis and evaluation of novel HDAC inhibitors as potential antitumor agents (2014) 
19. Design, synthesis, 3D pharmacophore, QSAR, and docking studies of carboxylic acid derivatives as Histone Deacetylase inhibitors and cytotoxic agents (2014) 
20. Discovery of a small molecule agonist of phosphatidylinositol 3-kinase p110α that reactivates latent HIV-1 (2014) 
21. In Vivo Imaging of Histone Deacetylases (HDACs) in the Central Nervous System and Major Peripheral Organs (2014) 
22. Kinetic method for the large-scale analysis of the binding mechanism of histone deacetylase inhibitors(2014) 
23. ive HDAC Inhibition for the Disruption of Latent HIV-1 Infection (2014) 
24. The effect of various zinc binding groups on inhibition of histone deacetylases 1-11 (2014) 
25. Thermodynamics of ligand binding to histone deacetylase like amidohydrolase from Bordetella/Alcaligenes (2014) 
26. A ive HDAC 1/2 inhibitor modulates chromatin and gene expression in brain and alters mouse behavior in two mood-related tests (2013) 
27. Class I HDAC imaging using [ (3)H]CI-994 autoradiography (2013) 
28. Crebinostat: a novel cognitive enhancer that inhibits histone deacetylase activity and modulates chromatin-mediated neuroplasticity (2013) 
29. FDG-PET imaging reveals local brain glucose utilization is altered by class I histone deacetylase inhibitors (2013) 
30. Highly ligand efficient and ive N-2-(Thioethyl)picolinamide histone deacetylase inhibitors inspired by the natural product psammaplin A (2013) 
31. Imaging epigenetic regulation by histone deacetylases in the brain using PET/MRI with ¹⁸F-FAHA(2013) 
32. Structural basis for the inhibition of histone deacetylase 8 (HDAC8), a key epigenetic player in the blood fluke Schistosoma mansoni (2013) 
33. Thioester derivatives of the natural product psammaplin A as potent histone deacetylase inhibitors(2013